Authorization

As Alzheimer’s costs soar, startups like Neurotrack raise cash to diagnose and treat the disease

As studies show that early diagnosis and preventative therapies can help prevent the onset of Alzheimer’s, startups that are working to diagnose the disease earlier are gaining more attention and funding.
That’s a boon to companies like Neurotrack, which closed on $21 million in new financing led by the company’s previous investor, Khosla Ventures, with participation from new investors Dai-ichi Life and SOMPO Holdings.
Last year, the Japanese life insurance company, Dai-ichi Life partnered with Neurotrack to roll out a cognitive assessment tool to the company’s customers in Japan.
And earlier this year, the Japanese health insurer, SOMPO conducted a 16-week pilot with Neurotrack, where more than 550 of SOMPO’s employees took Neurotrack’s test and followed the Memory Health Program for four months. Neurotrack and SOMPO are now working to deepen and extend their partnership.
“As the global crisis around Alzheimer’s continues to grow, the private sector is joining government and nonprofits to address the problem in their markets. In Japan, for example, traditional insurance companies are developing novel solutions that incorporate Neurotrack’s products to advance better memory health among its population,” said Elli Kaplan, Neurotrack Co-founder and CEO. “These partnerships are innovative models that we hope to replicate in other markets, enabling traditional insurance companies to create new markets while helping to address the Alzheimer’s crisis. And now they’re also investing in our company so these companies have two ways of doing well by doing good.”
Neurodegenerative disorders are becoming a more serious issue for the island nation — and the rest of the world. In fact, over the weekend the G20 first raised the possibility that aging populations could be a global risk.
“Most of the G20 nations already experience or will experience ageing,” Bank of Japan governor Haruhiko Kuroda, told reporters from Agence France Presse. “We need to discuss problems that arise with societal aging and how to deal with them.”
In the U.S., the estimated cost of caring for Americans with Alzheimer’s and other dementias was an estimated $277 billion in 2018, according to a study cited by WebMD. Roughly $186 billion of those costs are borne by Medicare and Medicaid with another $60 billion in payments coming out-of-pocket. That number could top $1.1 trillion by 2050, according to the same report.
Neurotrack uses cognitive assessments that follow eye movements using the camera on a computer or mobile phone to create a baseline for cognitive functions. The company then uses a combination of brain training and diet, exercise, and sleep adjustments to try and improve cognitive function and health.
Its technology is one of several different approaches startups are taking to try and provide early diagnoses and potential preventative measures against the disease.
MyndYou is another company tackling neurodegenerative diagnostics uses an app to monitor movement among its users. The company assesses that data to determine whether there may be any issues related to cognitive function.  It recently partnered with the Japanese company Mizuho to test its efficacy among Japan’s aging population.

MyndYou partners with Mizuho to expand senior care services assessing cognitive degeneration
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
242526272829